Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
Titel:
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
Auteur:
Chedid, Silwan Rivera, Edgardo Frye, Debbie K. Ibrahim, Nuhad Esteva, Francisco Valero, Vicente Hortobagyi, Gabriel Mettinger, Karl L. Cristofanilli, Massimo